Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth
Qi Pan, Yvan H. Chanthery, Wei‐Ching Liang et al. · Cancer Cell · 2007
Cited by 532 works. doi:10.1016/j.ccr.2006.10.018 Open-access PDF
Authors
- Qi Pan
- Yvan H. Chanthery
- Wei‐Ching Liang
- Scott S. Stawicki
- Judy Mak
- Nisha Rathore
- Raymond K. Tong
- Joe Kowalski
- Sharon Fong Yee
- Glenn Pacheco
- Sarajane Ross
- Zhiyong Cheng
- Jennifer E. LeCouter
- Gregory D. Plowman
- Franklin V. Peale Jr.
- Alexander Koch
- Yan Wu
- Anil Bagri
- Marc Tessier‐Lavigne
- Ryan J. Watts
References
- Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor
- A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
- Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
- Angiogenesis as a therapeutic target
- VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia
- Neuropilin Is a Receptor for the Axonal Chemorepellent Semaphorin III
- Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells
- Neuropilin Is a Semaphorin III Receptor
- Lessons from phase III clinical trials on anti-VEGF therapy for cancer
- A requirement for neuropilin-1 in embryonic vessel formation